Loading…
avatar for Yoko Aoi

Yoko Aoi

Pharmaceuticals and Medical Devices Agency (PMDA)
Principal reviewer, Office of New Drug V
Dr. Yoko Aoi is a principal reviewer of Office of New Drug V responsible for review and scientific advice on oncology drugs. After joining PMDA, Dr. Aoi was involved in review and scientific advice on new drugs for rheumatoid arthritis, asthma, COPD etc. (2011-2016) and planning and coordinating international activities such as PMDA Asia Training Center (2016-2019). In addition, Dr. Aoi is participating in Orphan drugs WG which investigates problems in development and application review, and proposes support measures in order to contribute to the orphan drug development. Moreover, Dr. Aoi is working on ICH E17 EWG/IWG as Deputy Topic Leader from 2014. Dr. Aoi holds a PhD from Tokyo Dental and Medical University.